NCT00265759View on ClinicalTrials.gov

Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

622

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

August 31, 2012

Study Completion Date

November 27, 2019

Conditions
Breast Cancer
Interventions
DRUG

anastrozole

Given PO

DRUG

exemestane

Given PO

DRUG

letrozole

Given PO

PROCEDURE

Therapeutic Conventional Surgery

Undergo partial or radical mastectomy or lumpectomy with or without lymph node dissection

Trial Locations (3)

63110

Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, St Louis

78041

Doctor's Hospital of Laredo, Laredo

77030-4009

M. D. Anderson Cancer Center at University of Texas, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Cancer and Leukemia Group B

NETWORK

lead

Alliance for Clinical Trials in Oncology

OTHER

NCT00265759 - Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer | Biotech Hunter | Biotech Hunter